[1]
Balaban, A.T.; Oniciu, D.C.; Katritzky, A.R. Chem. Rev., 2004, 104(5), 2777-2812.
[2]
Katritzky, A.R.; Rees, C.W.; Scriven, E.F.V. Comprehensive Heterocyclic Chemistry: A Review of the Literature 1982-1995: The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds, 1st ed; Pergamon: Oxford, New York, 1996.
[3]
Gomtsyan, A. Chem. Heterocycl. Compd., 2012, 48(1), 7-10.
[4]
Baumann, M.; Baxendale, I.R. Beilstein J. Org. Chem., 2013, 9, 2265-2319.
[5]
Pereira, J.A.; Pessoa, A.M.; Cordeiro, M.N.D.S.; Fernandes, R.; Prudencio, C.; Noronha, J.P.; Vieira, M. Eur. J. Med. Chem., 2015, 97, 664-672.
[6]
Matuszczak, B.; Pekala, E.; Mueller, C.E. Arch. Pharm. (Weinheim,
Ger.), 1998, 331(5), 163-169.
[7]
Matuszczak, B.; Mueller, C.E. Preparation of triazoloquinoxalines
as human A1, A2a, A2b and A3 adenosine receptor ligands, WO
2003053973 A1 Jul 3, 2003.
[8]
Matuszczak, B. unpublished results.
[9]
Romer, D.R. J. Heterocycl. Chem., 2009, 46(2), 317-319.
[10]
Sarges, R.; Howard, H.R.; Browne, R.G.; Lebel, L.A.; Seymour, P.A.; Koe, B.K. J. Med. Chem., 1990, 33(8), 2240-2254.